Zettrol Indications/Uses

Primary Hypercholesterolemia: Ezetimibe, administered with an HMG-CoA reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C) and to increase high-density lipoprotein cholesterol (HDL-C) in adult and adolescent (10-17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Ezetimibe, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia.
Prevention of Cardiovascular Disease: Ezetimibe, administered with a statin, is indicated to reduce the risk of cardiovascular events (Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease (CHD).
Prevention of Major Cardiovascular Events in Chronic Kidney Disease: Ezetimibe, administered with simvastatin, is indicated to reduce the risk of major cardiovascular events in patients with chronic kidney disease.
Homozygous Familial Hypercholesterolemia (HoFH): Ezetimibe, administered with a statin, is indicated for the reduction of elevated total-C and LDL-C levels in adult and adolescent (10 to 17 years of age) patients with HoFH. Patients may also receive adjunctive treatments (e.g. LDL apheresis).
Homozygous Sitosterolemia (Phytosterolemia): Ezetimibe, with diet is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.